Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Just hours after GRAP-3 restrictions were implemented, authorities tightened pollution controls in Delhi and surrounding areas on Saturday evening by moving to GRAP-4.

Earlier in the afternoon, the Commission for Air Quality Management (CAQM)—the central agency responsible for monitoring and managing pollution in Delhi and neighbouring states—had imposed GRAP-3 curbs as the Air Quality Index (AQI) surpassed 400, entering the ‘Severe’ category.

By evening, the CAQM reported that the AQI, which was 431 at 4 pm, continued to rise and reached 441 by 6 pm. Under the GRAP system, air quality is divided into four levels: Poor (AQI 201–300), Very Poor (AQI 301–400), Severe (AQI 401–450), and Severe Plus (AQI above 450).

The CAQM stated, “Considering the current air quality trend and to prevent further deterioration in the region, the Sub-Committee on GRAP has decided to implement all measures under Stage IV of the existing GRAP – ‘Severe+’ Air Quality (Delhi AQI > 450) – with immediate effect across the entire NCR. These measures are in addition to the actions already in place under Stages I, II, and III.”

The commission added that the primary reason for the worsening AQI was the weak Western Disturbance moving toward north-west India, rather than local emissions.

GRAP 4 In Delhi: Schools Shift to Hybrid Classes

While schools in Delhi remain open, classes for several grades have moved to a hybrid format, combining both in-person and online learning. The Delhi Directorate of Education (DDE) issued a circular directing all government, aided, and private schools under DOE, NDMC, MCD, and Delhi Cantonment Board to adopt hybrid classes for students up to Class IX and XI wherever online teaching is feasible.

The circular, dated December 13, states: “All Heads of Schools…are directed to conduct classes in schools for children up to Class IX and XI in a ‘Hybrid Mode’ i.e., both physical and online mode (wherever online mode is feasible) with immediate effect until further orders.”

GRAP 4 In Delhi: Are Delhi Schools Open Today?

Yes, all schools under the Delhi Directorate of Education remain open. Students up to Class IX and Class XI can attend classes either physically or online, depending on what they or their parents choose. The hybrid arrangement will continue until further notice. The directive also applies to schools managed by NDMC, MCD, and Delhi Cantonment Board. School authorities have been asked to promptly inform parents and guardians about the arrangements.

GRAP 4 Activated as Pollution Worsens

The move comes after the Commission for Air Quality Management (CAQM) declared Stage 4 of GRAP with immediate effect, as Delhi’s Air Quality Index (AQI) surged into the ‘severe’ category. At 6 am on Sunday, the AQI in the city stood at 462, according to the Central Pollution Control Board’s Sameer app.

GRAP 4 In Delhi: Restrictions Under Stage 4

Stage 4 maintains all measures from Stage 3 and introduces stricter curbs to limit pollution. Among the new restrictions is a total ban on truck traffic entering Delhi, except for vehicles carrying essential goods or providing critical services. Trucks powered by LNG, CNG, electricity, and BS-VI diesel are exempt from the ban.

A widely sold nasal spray is being pulled from shelves across the United States after tests revealed mold and microbial contamination, prompting officials to urge consumers to stop using it right away.

MediNatura New Mexico issued a voluntary recall of ReBoost Nasal Spray on Wednesday, the US Food and Drug Administration said in a public notice. The action follows findings that one specific lot of the product contained yeast and mold, along with unsafe levels of microbial contamination.

Laboratory testing also identified the presence of Achromobacter, a type of bacteria that can cause infections, particularly in people with weakened immune systems. The FDA has advised customers to immediately discontinue use of the affected nasal spray.

Nasal Spray Recall: FDA Flags Microbial and Mold Contamination

MediNatura New Mexico Inc. has voluntarily recalled its ReBoost Nasal Spray after the product was found to contain yeast, mold, and microbial contamination. One of the organisms identified was the bacteria Achromobacter, detected at levels higher than safety limits, according to the US Food and Drug Administration.

The FDA warned that use of the spray could result in severe health effects, particularly for people with weakened immune systems. The agency noted a real risk of serious and potentially life-threatening infections in this group.

Nasal Spray Recall: Possible Symptoms to Watch For

The Hawaii State Department of Health, which also issued a recall notice, listed symptoms that may be linked to the contaminated spray. These include fever, sinus swelling, headaches, facial pain or pressure, and numbness in the face.

Consumers who notice any of these symptoms after using the product have been advised to contact a doctor or healthcare provider.

Nasal Spray Recall: No Adverse Events Reported So Far

As of December 10, MediNatura said it had not received any reports of health problems related to the recalled nasal spray. This information was confirmed by both the FDA and the Hawaii health department.

As per NBC, the nasal spray company was contacted for comment but did not receive a response by the time of publication.

Nasal Spray Recall: About the Product

ReBoost Nasal Spray is a homeopathic product that contains echinacea and other natural ingredients. The company markets it as a remedy for nasal congestion and related symptoms.

Nasal Spray Recall: Which Lots Are Affected

The recall applies to sprays packaged in a white and yellow box containing a 20 mL bottle. The affected lot number is 224268, with an expiration date of December 2027. The product carries NDC number 62795-4005-9 and UPC 787647101863.

What Consumers Should Do

The FDA has urged customers to stop using the nasal spray right away. Those who bought it directly from MediNatura can request a refund by emailing recall@medinatura.com. Consumers who purchased it through other retailers should return it to the place of purchase.

The product was sold both online and in physical stores across the United States.

Danish drugmaker Novo Nordisk has officially introduced its widely known diabetes medication Ozempic in India, pricing the starter dose of 0.25 mg at ₹2,200 per week. According to a Reuters report, the injectable medicine will be available in three strengths in the country: 0.25 mg, 0.5 mg and 1 mg.

Ozempic is a once-weekly injectable prescribed for people living with type 2 diabetes.

Ozempic Price In India

The weekly injection received approval from the US Food and Drug Administration in 2017 for treating type 2 diabetes. Since then, it has grown into a global blockbuster and is also commonly prescribed off-label for weight loss because of its appetite-suppressing effects.

The lowest strength will cost ₹2,200 per week. Prices for the higher doses have also been announced, as per the Reuters report.

Here are the details:

• 1 mg dose: ₹11,175/month
• 0.5 mg dose: ₹10,170/month
• 0.25 mg dose: ₹8,800/month

All you need To know About Ozempic

India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), approved Ozempic, also known as semaglutide, in October this year for adults with type 2 diabetes.

As per the US FDA, Ozempic is prescribed along with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major cardiovascular events in adults with type 2 diabetes who already have heart disease.

As per NDTV Profit, currently, Wegovy is priced at Rs 2,712 per week for the 0.25 mg dose, while the 0.5 mg dose costs Rs 3,462 weekly. The 1 mg dose is also priced at Rs 3,462 per week, and the 1.7 mg dose is available at Rs 4,100 per week. Mounjaro (tirzepatide), a combination therapy of GLP-1 receptor agonist and GIP that helps improve blood sugar control in adults with type 2 diabetes when paired with a healthy diet and regular exercise, is priced at Rs 13,500 per month for the 2.5 mg dose.

How Does Ozempic Help In Weight Loss?

Ozempic mimics the action of a naturally occurring hormone called GLP-1. Here’s how it supports weight loss, as outlined in an earlier HT report.

• It boosts insulin release when blood sugar levels increase.
• It slows down the emptying of food from the stomach, helping people feel full for longer after meals.
• At higher doses, it can also curb appetite, which may aid weight management efforts.

Possible Side-Effects Of Ozempic

As previously reported by Mayo Clinic, some potential side-effects of Ozempic include:

• An increased risk of inflammation of the pancreas.
• Possible gallbladder-related problems.
• According to the FDA, the most commonly reported side effects, seen in at least 5 per cent of patients taking Ozempic, include nausea, vomiting, diarrhoea, abdominal pain and constipation.

This article is intended for informational purposes only and should not be taken as a replacement for professional medical advice.